0.1689  0.017 (11.12%)		06-18 16:00
Open: 0.1542 High: 0.17 Volume: 9,212,702		Pre. Close: 0.152 Low: 0.1542 Market Cap: 1(M)

Short term
Mid term
Targets	6-month :	0.23	1-year :	0.27
Resists	First :	0.2	Second :	0.23
Pivot price	0.16
Supports	First :	0.15	Second :	0.12
MAs	MA(5) :	0.15	MA(20) :	0.17
	MA(100) :	0.39	MA(250) :	1.76
MACD	MACD :	-0.1	Signal :	-0.1
%K %D	K(14,3) :	55.1	D(3) :	51.3
RSI	RSI(14): 43.7
52-week	High :	19.2	Low :	0.12

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ CLDI ] has closed above bottom band by 48.6%. Bollinger Bands are 81.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 58 bars. This is a sign that the market may be about to initiate a new trend.

If tomorrow:	Open lower	Open higher
High:	0.17 - 0.17	0.17 - 0.17
Low:	0.15 - 0.15	0.15 - 0.15
Close:	0.17 - 0.17	0.17 - 0.17

Calidi Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on immuno-oncology, dedicated to developing advanced immunotherapies for various cancers. The company's innovative approach centers on utilizing powerful, allogeneic (donor-derived) stem cells as specialized carriers for anti-tumor agents. This technology is being advanced to address a range of oncological conditions, including aggressive brain tumors (high-grade gliomas) and other solid malignancies. Calidi's proprietary cell-based delivery systems are expertly designed to safeguard, amplify, and boost the therapeutic effects of oncolytic viruses. This strategic delivery method aims to achieve superior treatment efficacy and enhance patient safety. The company's clinical pipeline features two primary candidates: NeuroNova, which employs allogeneic neural stem cells loaded with an oncolytic adenovirus specifically for the treatment of high-grade gliomas; and SuperNova, which utilizes allogeneic adipose-derived mesenchymal stem cells to deliver the tumor-selective CAL1 oncolytic vaccinia virus for advanced metastatic solid tumors. Established in 2014, Calidi Biotherapeutics operates out of San Diego, California.

Thu, 18 Jun 2026
Calidi Biotherapeutics (CLDI) stockholders back all proposals at 2026 annual meeting - Stock Titan

Thu, 18 Jun 2026
Calidi Biotherapeutics Inc (CLDI) Valuation: PE, PB & Fair Value Analysis - TradingKey

Thu, 18 Jun 2026
Calidi Biotherapeutics Inc (CLDI) Financial Health: Profitability & Balance Sheet Analysis - TradingKey

Thu, 18 Jun 2026
Calidi Biotherapeutics Inc (CLDI) Institutional Confidence - TradingKey

Tue, 16 Jun 2026
Calidi Biotherapeutics Receives Positive Pre-IND Feedback from US FDA for CLD-401 Indicating Agreement on its Current Development Strategy as it Advances Towards a First-in-Human Study - The Manila Times

Tue, 16 Jun 2026
FDA feedback sets path for Calidi CLD-401 oncolytic virus trial - Stock Titan

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Outperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: AMEX
Sector: Healthcare
Industry: Biotechnology
Shares Out	0 (M)
Shares Float	0 (M)
Held by Insiders	0 (%)
Held by Institutions	0 (%)
Shares Short	0 (K)
Shares Short P.Month	0 (K)

EPS	0
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	0 %
Return on Equity (ttm)	0 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	0
Qtrly Earnings Growth	0 %
Operating Cash Flow	0 (M)
Levered Free Cash Flow	0 (M)

PE Ratio	0
PEG Ratio	0
Price to Book value	0
Price to Sales	0
Price to Cash Flow	0

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.